FI944676A0 - Vaccin ineehållande icke-joniska ytaktiva vesikler - Google Patents

Vaccin ineehållande icke-joniska ytaktiva vesikler

Info

Publication number
FI944676A0
FI944676A0 FI944676A FI944676A FI944676A0 FI 944676 A0 FI944676 A0 FI 944676A0 FI 944676 A FI944676 A FI 944676A FI 944676 A FI944676 A FI 944676A FI 944676 A0 FI944676 A0 FI 944676A0
Authority
FI
Finland
Prior art keywords
pct
vesicles
ionic surfactant
sec
containing non
Prior art date
Application number
FI944676A
Other languages
English (en)
Finnish (fi)
Other versions
FI944676A (sv
Inventor
James Alexander
Brewer James Macdonald
Original Assignee
Proteus Molecular Design
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteus Molecular Design filed Critical Proteus Molecular Design
Publication of FI944676A publication Critical patent/FI944676A/sv
Publication of FI944676A0 publication Critical patent/FI944676A0/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/45—Toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
FI944676A 1992-04-07 1994-10-06 Vaccin ineehållande icke-joniska ytaktiva vesikler FI944676A0 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929207731A GB9207731D0 (en) 1992-04-07 1992-04-07 Improvements in or relating to vaccines
PCT/GB1993/000716 WO1993019781A1 (en) 1992-04-07 1993-04-06 Vaccines containing non-ionic surfactant vesicles

Publications (2)

Publication Number Publication Date
FI944676A FI944676A (sv) 1994-10-06
FI944676A0 true FI944676A0 (sv) 1994-10-06

Family

ID=10713695

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944676A FI944676A0 (sv) 1992-04-07 1994-10-06 Vaccin ineehållande icke-joniska ytaktiva vesikler

Country Status (16)

Country Link
US (1) US5679355A (sv)
EP (1) EP0634937B1 (sv)
JP (1) JP2690620B2 (sv)
KR (1) KR950700758A (sv)
CN (1) CN1085449A (sv)
AT (1) ATE158185T1 (sv)
AU (1) AU3899793A (sv)
CA (1) CA2132547C (sv)
DE (1) DE69314020T2 (sv)
FI (1) FI944676A0 (sv)
GB (1) GB9207731D0 (sv)
HU (1) HUT69935A (sv)
NO (1) NO943739L (sv)
NZ (1) NZ251402A (sv)
WO (1) WO1993019781A1 (sv)
ZA (1) ZA932491B (sv)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003035A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
US5919466A (en) * 1993-10-01 1999-07-06 Gerbu Biotechnik Gmbh Method for improving the yield of immunoantibodies in the vaccination of animals and humans
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
DE69435244D1 (de) * 1993-12-17 2009-11-26 Novavax Inc Verfahren zur übertragung eines biologisch aktiven materials an eine zelle
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
GB9515868D0 (en) * 1995-08-02 1995-10-04 Proteus Molecular Design Therapeutic method
GB9600471D0 (en) * 1996-01-10 1996-03-13 Univ London Pharmacy Drug delivery system
KR20010042573A (ko) * 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
US6494865B1 (en) * 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
FR2802422B1 (fr) * 1999-12-21 2002-08-09 Capsulis Structures mixtes resultant de l'incorporation d'une macromolecule biologique, en particulier d'adn, dans une phase structuree d'amphiphiles et vesicules obtenues a partir de ces structures
GB9930591D0 (en) * 1999-12-23 2000-02-16 Univ London Component for vaccine
FI112825B (sv) * 2001-07-11 2004-01-15 Antti Nissinen Förfarande för påvisning av alkoholkonsumtion, medel som används vid förfarandet och deras framställning
KR20050025306A (ko) * 2002-07-03 2005-03-14 애프톤 코포레이션 리포좀 백신
CN1711074B (zh) * 2002-11-15 2010-10-06 尼普洛株式会社 脂质体
FR2850872A1 (fr) * 2003-02-12 2004-08-13 Ethypharm Sa Composition vaccinale destinee a induire une reponse immunitaire contre le virus responsable du sida
BRPI0414021B1 (pt) 2003-08-28 2023-09-26 Becton, Dickinson And Company Dispositivo de injeção intradérmica
CN101313216A (zh) * 2005-09-22 2008-11-26 普洛茨股份有限公司 酵母突变体中产生的糖基化多肽及其使用方法
CA2735724C (en) 2008-06-19 2018-07-24 Variation Biotechnologies Inc. Compositions and methods for treating influenza
EP3173125B1 (en) 2008-07-30 2019-03-27 Ecole Polytechnique Fédérale de Lausanne Apparatus for optimized stimulation of a neurological target
EP3563902B1 (en) 2008-11-12 2021-07-14 Ecole Polytechnique Fédérale de Lausanne Microfabricated neurostimulation device
CA2767392C (en) 2009-07-06 2017-03-14 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
EP2506920B1 (en) 2009-12-01 2016-07-13 Ecole Polytechnique Fédérale de Lausanne Microfabricated surface neurostimulation device and method of making the same
US9549708B2 (en) 2010-04-01 2017-01-24 Ecole Polytechnique Federale De Lausanne Device for interacting with neurological tissue and methods of making and using the same
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
CN103298836B (zh) * 2011-01-07 2017-03-08 东亚合成株式会社 用于获得抗疏水性肽抗体的抗原的制备方法
EP2662387A4 (en) * 2011-01-07 2015-08-05 Seiko Epson Corp ANTIBODY AGAINST THE SIGNAL PEPTIDE OF THE AMYLOID PRECURSOR PROTEIN
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
AU2012205315B2 (en) * 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
US20150079077A1 (en) * 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
US9370182B2 (en) 2012-05-28 2016-06-21 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
WO2014061749A1 (ja) 2012-10-18 2014-04-24 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用
US11311718B2 (en) 2014-05-16 2022-04-26 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
US10966620B2 (en) 2014-05-16 2021-04-06 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
US9403011B2 (en) 2014-08-27 2016-08-02 Aleva Neurotherapeutics Leadless neurostimulator
WO2017134587A1 (en) 2016-02-02 2017-08-10 Aleva Neurotherapeutics, Sa Treatment of autoimmune diseases with deep brain stimulation
GB201612108D0 (en) * 2016-07-12 2016-08-24 Univ Strathclyde Preperation of non-ionic surfactant vesicles and variants
US10702692B2 (en) 2018-03-02 2020-07-07 Aleva Neurotherapeutics Neurostimulation device

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
FR2571963B1 (fr) * 1984-10-24 1987-07-10 Oreal Composition a usage cosmetique ou pharmaceutique contenant des niosomes et au moins un polyamide hydrosoluble et procede de preparation de cette composition.
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
FR2597346B1 (fr) * 1986-04-22 1989-08-18 Oreal Procede pour faciliter la formation de niosomes en dispersion dans une phase aqueuse et pour ameliorer leur stabilite et leur taux d'encapsulation, et dispersions correspondantes.
US4855090A (en) * 1987-03-13 1989-08-08 Micro-Pak, Inc. Method of producing high aqueous volume multilamellar vesicles
JP2617346B2 (ja) * 1987-03-13 1997-06-04 マイクロ ベシキュラー システムズ，インコーポレイテッド 表面活性剤とステロイドから形成される脂質小胞
GB8713240D0 (en) * 1987-06-05 1987-07-08 Proteus Biotech Ltd Hormones
LU87449A1 (fr) * 1989-02-09 1990-09-19 Oreal Procede de fabrication de mousses utilisables dans les domaines cosmetique et pharmaceutique et mousses obtenues par ce procede
IT1238343B (it) * 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
DE69227580T2 (de) * 1991-03-28 1999-04-08 Micro Pak Inc Wasser-in-öl-emulsionen, die lipidvesikel enthalten

Also Published As

Publication number Publication date
DE69314020D1 (de) 1997-10-23
GB9207731D0 (en) 1992-05-27
HU9402904D0 (en) 1995-01-30
CA2132547A1 (en) 1993-10-14
NO943739D0 (no) 1994-10-05
US5679355A (en) 1997-10-21
JPH07505389A (ja) 1995-06-15
AU3899793A (en) 1993-11-08
FI944676A (sv) 1994-10-06
ATE158185T1 (de) 1997-10-15
KR950700758A (ko) 1995-02-20
EP0634937A1 (en) 1995-01-25
EP0634937B1 (en) 1997-09-17
NZ251402A (en) 1996-10-28
CN1085449A (zh) 1994-04-20
DE69314020T2 (de) 1998-08-06
HUT69935A (en) 1995-09-28
JP2690620B2 (ja) 1997-12-10
NO943739L (no) 1994-10-05
WO1993019781A1 (en) 1993-10-14
CA2132547C (en) 2000-06-06
ZA932491B (en) 1993-11-02

Similar Documents

Publication Publication Date Title
FI944676A0 (sv) Vaccin ineehållande icke-joniska ytaktiva vesikler
DK0705109T3 (da) Adjuvanser til vacciner mod respiratorisk syncytialvirus
AU4951196A (en) Vaccines for plague
DE60012711D1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
ES2118963T3 (es) Vacunas combinadas, que contienen antigeno de superficie de la hepatitis b y otros antigenos.
DK0528859T3 (da) Oral vaccine, som omfatter antigen knyttet til overfladen af røde blodlegemer
AU2001295673A1 (en) Vaccine composition
DK0745387T3 (da) Adjuvanser til virale vacciner
ATE153071T1 (de) Neue proteinhaltige partikeln
IL130075A0 (en) A vaccine for eliciting an immune response to an antigen in an animal
DK1267924T3 (da) Immunterapeutiske metoder og sammensætninger
FI924457A (fi) Kompositioner och behandlingsfoerfarande foer lunginflammation i djur
GEP20053446B (en) Adjuvant Combination Formulations
DK0563254T3 (da) Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
ATE185073T1 (de) Impfstoff zubereitungen
NO175846C (no) Fremgangsmåte for å oppnå et immunogen
DE69322960D1 (de) Empfängnisverhütender impfstoff
CO5070581A1 (es) Vacunas

Legal Events

Date Code Title Description
FD Application lapsed